Released Aug 14, 2017, after the close
10-Q filed Aug 14, 2017, 45 days after period end · 0001564590-17-017677
Q2 2017 · 10-Q
Revenue$1.03M$1.03M −0.1% vs Q2 2016−0.1% vs Q1 2017
Net Income-$9.65M-$9.65M N/M vs Q2 2016N/M vs Q1 2017
EPS Diluted-$0.23-$0.23 N/M vs Q2 2016N/M vs Q1 2017
Operating Income-$9,570,000N/M
Operating Cash Flowderived-$8,872,000N/M
Free Cash Flowderived-$9,283,000N/M
Margins · derived
Operating margin-932.7%−153.4 pt vs Q2 2016
Net margin-940.1%−121.4 pt vs Q2 2016
What the release said
The release
Same quarter
| Metric | Q2 2017 | Q2 2016 | Q2 2015 | Q2 2014 |
|---|---|---|---|---|
| Revenue | $1.03M | $1.03M | $329.00K | — |
| Net Income | -$9.65M | -$8.41M | -$7.78M | -$6.07M |
| EPS Diluted | -$0.23 | -$0.29 | -$0.33 | -$0.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR